Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2020
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Myeloma - Pipeline Review, H1 2020, provides an overview of the Multiple Myeloma (Oncology) pipeline landscape.
Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. Multiple myeloma mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Myeloma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Multiple Myeloma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Multiple Myeloma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 10, 105, 118, 4, 10, 165, 29 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 16, 19, 9, 32 and 8 molecules, respectively.
Multiple Myeloma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Multiple Myeloma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Multiple Myeloma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Multiple Myeloma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Myeloma (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Multiple Myeloma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Multiple Myeloma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Introduction
Multiple Myeloma (Kahler Disease) - Overview
Multiple Myeloma (Kahler Disease) - Therapeutics Development
Multiple Myeloma (Kahler Disease) - Therapeutics Assessment
Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development
Multiple Myeloma (Kahler Disease) - Drug Profiles
Multiple Myeloma (Kahler Disease) - Dormant Projects
Multiple Myeloma (Kahler Disease) - Discontinued Products
Multiple Myeloma (Kahler Disease) - Product Development Milestones
Appendix
Tables and Figures
List of Tables
Number of Products under Development for Multiple Myeloma (Kahler Disease), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by 4SC AG, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Aadi Bioscience Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by AbbVie Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by ABL Bio Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Acepodia Biotech Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Actinium Pharmaceuticals Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Active Biotech AB, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Adicet Bio Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Aduro BioTech Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Aeglea BioTherapeutics Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Affimed GmbH, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Agenus Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Allife Medical Science and Technology Co Ltd, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Allogene Therapeutics Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Ambrx Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Amgen Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Antengene Corp, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by APIM Therapeutics AS, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by APO-T BV, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Arcellx Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Templates Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by MolMed SpA, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Momenta Pharmaceuticals Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by MorphoSys AG, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Multitude therapeutics Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Mustang Bio Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Sorrento Therapeutics Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by SpecificiT Pharma Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Spectrum Pharmaceuticals Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Sphaera Pharma Pte Ltd, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by SpringWorks Therapeutics Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Starton Therapeutics Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Sunomix Therapeutics, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Surface Oncology Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Sutro Biopharma Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Suzhou Maximum Bio-tech Co Ltd, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by T-CURX GmbH, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by T-Knife GmbH, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by TaiGen Biotechnology Co Ltd, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Taiho Oncology Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by TaiRx Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Targazyme Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by TeneoBio Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Tiziana Life Sciences Plc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Tmunity Therapeutics Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Tolero Pharmaceuticals Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Transgene Biotek Ltd, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Trillium Therapeutics Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Triterpenoid Therapeutics Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Ube Industries Ltd, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Vaccibody AS, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Vaxil Bio Therapeutics Ltd, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Vichem Chemie Research Ltd, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Visterra Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Vycellix Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Vyriad Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by WindMIL Therapeutics Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Wugen Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Wuhan Bio-Raid Biotechnology Co Ltd, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Wuhan YZY Biopharma Co Ltd, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by XEME BioPharma Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Xiangxue Life Sciences, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by XNK Therapeutics AB, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Zhengda Tianqing Pharmaceutical Group Co Ltd, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Zovis Pharmaceuticals, H1 2020
Multiple Myeloma (Kahler Disease) - Dormant Projects, H1 2020
Multiple Myeloma (Kahler Disease) - Discontinued Products, H1 2020
Companies Mentioned
4SC AG
A. Menarini Industrie Farmaceutiche Riunite Srl
Aadi Bioscience Inc
AbbVie Inc
ABL Bio Inc
Acepodia Biotech Inc
Actinium Pharmaceuticals Inc
Active Biotech AB
Adicet Bio Inc
Aduro BioTech Inc
Aeglea BioTherapeutics Inc
Affimed GmbH
Agenus Inc
Allife Medical Science and Technology Co Ltd
Allogene Therapeutics Inc
Ambrx Inc
Amgen Inc
Anhui Anke Biotechnology (Group) Co Ltd
Antengene Corp
APIM Therapeutics AS
APO-T BV
Arcellx Inc
Ariz Precision Medicine Inc
Ascenta Therapeutics Inc
Ascentage Pharma Group International
Asclepius Technology Company Group Suzhou Co Ltd
Aslan Pharmaceuticals Ltd
AstraZeneca Plc
Atara Biotherapeutics Inc
Auransa Inc
Aurigene Discovery Technologies Ltd
Autolus Therapeutics Plc
Ayala Pharmaceuticals Inc
Bantam Pharmaceutical LLC
Bayer AG
Beijing Immunochina Medical Science & Technology Co Ltd
Beijing Sunbio Biotech Co Ltd
Bellicum Pharmaceuticals Inc
Betta Pharmaceuticals Co Ltd
BeyondSpring Inc
BioLineRx Ltd
Biomunex Pharmaceuticals
Biosion Inc
Biotest AG
BioVec Pharma Inc
BiVictriX Therapeutics Ltd
Boehringer Ingelheim International GmbH
Boryung ViGenCell Inc
Boston Biomedical Inc
Bristol-Myers Squibb Co
CanBas Co Ltd
Caribou Biosciences Inc
CARsgen Therapeutics Ltd
Cartesian Therapeutics Inc
CASI Pharmaceuticals Inc
CDR-Life Inc
Cell Source Inc
CellCentric Ltd
Cellectar Biosciences Inc
Cellectis SA
Celleron Therapeutics Ltd
Cellestia Biotech AG
Cello Therapeutics Inc
Cellular Biomedicine Group Inc
Celularity Inc
Celyad Oncology
Centrax International Inc
Cerecor Inc
Checkpoint Therapeutics Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chipscreen Biosciences Ltd
Chong Kun Dang Pharmaceutical Corp
CiMaas BV
Cleave Therapeutics Inc
Constellation Pharmaceuticals Inc
Corvus Pharmaceuticals Inc
CRISPR Therapeutics AG
CStone Pharmaceuticals Co Ltd
Curis Inc
Curocell Inc
Cyclacel Pharmaceuticals Inc
Cyteir Therapeutics Inc
Cytonus Therapeutics Inc
Cytovia Therapeutics Inc
Daiichi Sankyo Co Ltd
DC Prime BV
DeuteRx LLC
Diverse Biotech Inc
Eli Lilly and Co
Enceladus Pharmaceuticals BV
EpicentRx Inc
Epizyme Inc
eTheRNA Immunotherapies NV
Eureka Therapeutics Inc
ExCellThera Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Fera Pharmaceuticals LLC
Fortis Therapeutics Inc
Gadeta BV
Galileo Research srl
Gamida Cell Ltd
GemoPharm
Genenta Science srl
Genentech Inc
Genmab AS
Geron Corp
Gilead Sciences Inc
GlaxoSmithKline Plc
Gliknik Inc
GlycoMimetics Inc
Glycostem Therapeutics BV
GlyTR Therapeutics Inc
GP Pharm SA
Gracell Biotechnology Ltd
GT Biopharma Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
HaemaLogix Pty Ltd
Harbour BioMed
Harpoon Therapeutics Inc
Hebei Senlang Biotechnology Inc Ltd
Heidelberg Pharma AG
Helix BioPharma Corp
Helocyte Biosciences Inc
Hengenix Biotech Inc
Hinova Pharmaceuticals Inc
HitGen LTD
HRAIN Biotechnology Co Ltd
Hunan Siweikang Therapeutics Ltd
HuniLife Biotechnology Inc
Hutchison MediPharma Ltd
iCell Gene Therapeutics LLC
Ichnos Sciences Inc
IDAC Theranostics Inc
IDP Discovery Pharma SL
IGM Biosciences Inc
ImmuneTarget Inc
ImmunityBio Inc
Immunomedics Inc
Immunotech Biopharm Ltd
Incuron LLC
Incyte Corp
Indapta Therapeutics Inc
Inflection Biosciences Ltd
Inmune Bio Inc
Innovative Cellular Therapeutics Co Ltd
Intra-Immusg Pvt Ltd
Inven2 AS
Inventiva
IO Biotech ApS
Ionis Pharmaceuticals Inc
Ionova Life Science Co Ltd
Istesso Ltd
Iterion Therapeutics
Janpix Inc
Jiangsu Hengrui Medicine Co Ltd
JN Biosciences LLC
Johnson & Johnson
JSK Therapeutics Inc
Jubilant Therapeutics Inc
Juno Therapeutics Inc
Juventas Cell Therapy Ltd
JW Pharmaceutical Corp
Kangpu Biopharmaceuticals Ltd
Karyopharm Therapeutics Inc
Kiadis Pharma NV
Kleo Pharmaceuticals Inc
Klyss Biotech Inc
Komipharm International Co Ltd
Kymab Ltd
Laekna Therapeutics Shanghai Co Ltd
Leadiant Biosciences Inc
Les Laboratoires Servier SAS
Leukogene Therapeutics Inc
Ligand Pharmaceuticals Inc
Lokon Pharma AB
Luye Pharma Group Ltd
Mablink Bioscience
Machavert Pharmaceuticals LLC
Marker Therapeutics Inc
Max Biopharma Inc
MediGene AG
MedPacto Inc
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Miltenyi Biotec GmbH
MimiVax LLC
Modulation Therapeutics Inc
Molecular Partners AG
Molecular Templates Inc
MolMed SpA
Momenta Pharmaceuticals Inc
MorphoSys AG
Multitude therapeutics Inc
Mustang Bio Inc
Mycovia Pharmaceuticals Inc
Nanjing Bioheng Biotech Co Ltd
Nanjing CART Medical Technology Co Ltd
Nanjing Iaso Biotherapeutics Co Ltd
Nanjing Legend Biotech Co Ltd
NantKwest Inc
Nektar Therapeutics
Neonc Technologies Inc
NewBay Medical Technology Co Ltd
NexImmune Inc
Northlake International LLC
Novartis AG
Noxxon Pharma AG
Oncoceutics Inc
Oncodesign SA
OncoFusion Therapeutics Inc
Oncolytics Biotech Inc
Onconova Therapeutics Inc
OncoPep Inc
Oncopeptides AB
OncoTartis Inc
OncoTherapy Science Inc
One World Cannabis Ltd
Ono Pharmaceutical Co Ltd
Origincell Technology Group Co Ltd
Otsuka Pharmaceutical Co Ltd
PentixaPharm GmbH
Peptron Inc
PersonGen Anke Cellular Therapeutics Co Ltd
PersonGen Biomedicine Suzhou Co Ltd
Pfizer Inc
Pharma Mar SA
Phi Pharma SA
Phosplatin Therapeutics LLC
PI Therapeutics Ltd
Pimera Inc
Poseida Therapeutics Inc
Precision Biosciences Inc
Prescient Therapeutics Ltd
Protheragen Inc
Quadriga BioSciences Inc
Qwixel Therapeutics LLC
Rainier Therapeutics Inc
Rapa Therapeutics LLC
RAPT Therapeutics Inc
RedHill Biopharma Ltd
Regeneron Pharmaceuticals Inc
Rhizen Pharmaceuticals SA
Samus Therapeutics LLC
Sanofi
Seattle Genetics Inc
SELLAS Life Sciences Group Inc
Senhwa Biosciences Inc
Shanghai Bioray Laboratory Inc
Shanghai Theorion Pharmaceutical Co Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Shanghai Yingli Pharmaceutical Co Ltd
Shenogen Pharma Group Ltd
Shuttle Pharmaceuticals Inc
Sichuan Kelun Pharmaceutical Co Ltd
SignalRx Pharmaceuticals Inc
SignPath Pharma Inc
Sorrento Therapeutics Inc
SpecificiT Pharma Inc
Spectrum Pharmaceuticals Inc
Sphaera Pharma Pte Ltd
SpringWorks Therapeutics Inc
Starton Therapeutics Inc
Sunomix Therapeutics
Surface Oncology Inc
Sutro Biopharma Inc
Suzhou Maximum Bio-tech Co Ltd
T-CURX GmbH
T-Knife GmbH
TaiGen Biotechnology Co Ltd
Taiho Oncology Inc
TaiRx Inc
Takeda Pharmaceutical Co Ltd
Targazyme Inc
TeneoBio Inc
Tiziana Life Sciences Plc
Tmunity Therapeutics Inc
Tolero Pharmaceuticals Inc
Transgene Biotek Ltd
Trillium Therapeutics Inc
Triterpenoid Therapeutics Inc
Ube Industries Ltd
Vaccibody AS
Vaxil Bio Therapeutics Ltd
Vichem Chemie Research Ltd
Visterra Inc
Vycellix Inc
Vyriad Inc
WindMIL Therapeutics Inc
Wugen Inc
Wuhan Bio-Raid Biotechnology Co Ltd
Wuhan YZY Biopharma Co Ltd
XEME BioPharma Inc
Xiangxue Life Sciences
XNK Therapeutics AB
Zhengda Tianqing Pharmaceutical Group Co Ltd
Zovis Pharmaceuticals
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets